Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.…
Restart Life Advances BrainQ SuperFood Towards 2027 Production
Restart Life Advances BrainBalls Toward Planned 2027 Canadian Launch and U.S. Expansion
Restart Life Advances Licensed Intellectual Property Portfolio Toward Commercial Launch
Restart Life Sciences (CNSX: HEAL) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0650 CAD on 19 November 2026, down 35.0% over 52 weeks. Its 52-week range is 0.0650 CAD to 0.1350 CAD, and it trades at the bottom of that range.
Its market capitalisation is 4.06M CAD.
Restart Life Sciences reports return on equity of -108.0% and an operating margin of -376.1%.
It holds more cash than debt, a net cash position of 414.02K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.